

From: "Dr. Ulrich Gatzemeier" <pneumo.onko@t-online.de>
To: 'Jens Benn Sørensen' <jens.benn.soerensen@rh.regionh.dk>
Date: Friday, June 27, 2008 08:22AM
Subject: AW: Mesothelioma Treatment

Dear Jens,

you are completely right. Cisplatin/Alimta is one option in the treatment of pleuramesothelioma and there are no direct randomized data against other combinations like platin/vinorelbine. That fact I told to the journalist as well.

On the other hand there are no better historical data than due to cisplatin/Alimta in the "Vogelzang-trial". In consequence we try to give our patients with mesotheliomas if possible cisplatin/Alimta in 1st line and sometimes Gemcitabine in 2nd line. In patients with contraindications of cisplatin carboplatin is used as combination partner or in few cases we treat even with Alimta as single agent.

From the scientific pion of view and the published data it's still allowed and justified to treat patients with cisplatin/vinorelbine in 1st line and giving Alimta in 2nd line.

It's sometimes really difficult to explain this content to journalists because they are fixed and want to recognize only what they want to hear.

Hopefully we'll see us again very soon

Kind regards

Dr Ulrich Gatzemeier

Head Dep of Thoracic Oncology

Hospital Grosshansdorf

Woehrendamm 80

22927 Grosshansdorf

Tel 0049 4102 601261

Fax 0049 4102 601247

e-mail pneumo.onko@t-online.de

-----Ursprüngliche Nachricht-----

Von: Jens Benn Sørensen [mailto:jens.benn.soerensen@rh.regionh.dk]

Gesendet: Freitag, 20. Juni 2008 17:31

An: pneumo.onko@t-online.de

Betreff: Mesothelioma Treatment

Dear Ulrich,

It was indeed a pleasure to meet you during the advisory board meeting in Rome. I hope that you had a safe trip home.

During the meeting you told me about the danish TV-journalist who had interviewed you with camera on alimta treatment. Her thesis is that cisplatin + alimta is a regimen proven to be superior to all other published combination regimens and that all patients with MPM should be offered that treatment. She is claiming that our previous strategy using cisplatin + vinorelbine as 1st line and alimta as 2nd line is clearly inferior to a strategy using cisplatin + alimta as 1st line and another agent as 2nd line. Personally I disagree that this is scientifically proven, even though certainly cisplatin + alimta is a fine regimen and we also do use it.

I remember that you told me that you explained these issues to the journalist. However, most likely the TV-channel will cut the interview into pieces and the overall impression might be somewhat different from what was intended. Hence, it would be a great help for us if you would possibly send me just a short letter with a few sentences indicating your thoughts on this matter. I do know that you are busy and that many matters take your time but certainly I would very much appreciate your input.

Best wishes, yours sincerely,

Jens Benn Sorensen, MD

Dept. Oncology, FinsenCentre/National University Hospital

Copenhagen

jens.benn.soerensen@rh.regionh.dk

=